Drug interactions between Lipitor and Prezista
| Results for the following 2 drugs: |
|---|
| Lipitor (atorvastatin) |
| Prezista (darunavir) |
Interactions between your selected drugs
atorvastatin ↔ darunavir
Applies to:Lipitor (atorvastatin) and Prezista (darunavir)
ADJUST DOSE: Coadministration with darunavir/ritonavir may increase the plasma concentrations of atorvastatin. The mechanism is darunavir/ritonavir inhibition of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of atorvastatin. In 15 study subjects, administration of atorvastatin 10 mg once a day in combination with darunavir/ritonavir (300 mg/100 mg twice a day) resulted in similar atorvastatin systemic exposure (AUC) compared to administration of atorvastatin 40 mg once a day alone.
MANAGEMENT: Because high levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity including severe myopathy and rhabdomyolysis, atorvastatin should be initiated at the lowest possible dosage when prescribed with darunavir/ritonavir. The dosage may be increased gradually based on clinical response. Fluvastatin and rosuvastatin may be safer alternatives in patients treated with protease inhibitors, since they are not metabolized by CYP450 3A4. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
